首站-论文投稿智能助手
典型文献
Spatio-temporal delivery of both intra-and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses
文献摘要:
For cancer immunotherapy,triggering toll-like receptors(TLRs)in dendritic cells(DCs)can potentiate antigen-based immune responses.Nevertheless,to generate robust and long-lived immune re-sponses,a well-designed nanovaccine should consider different locations of TLRs on DCs and co-deliver both antigens and TLR agonist combinations to synergistically induce optimal antitumor immunity.Here-in,we fabricated lipid-polymer hybrid nanoparticles(LPNPs)to spatio-temporally deliver model antigen ovalbumin(OVA)on the surface of the lipid layer,TLR4 agonist monophosphoryl lipid A(MPLA)within the lipid layer,and TLR7 agonist imiquimod(IMQ)in the polymer core to synergistically activate DCs by both extra-and intra-cellular TLRs for enhancing adaptive immune responses.LPNPs-based nanovac-cines exhibited a narrow size distribution at the mean diameter of 133.23 nm and zeta potential of-2.36 mV,showed a high OVA loading(around 70.83 μg/mg)and IMQ encapsulation efficiency(88.04%).Our data revealed that LPNPs-based nanovaccines showed great biocompatibility to immune cells and an excellent ability to enhance antigen internalization,thereby promoting DCs maturation and cytokines production.Compared to Free OVA,OVA-LPNPs promoted antigen uptake,lysosome escape,depot effect and migration to secondary lymphatic organs.In vivo immunization showed that IMQ-MPLA-OVA-LPNPs with dual agonists induced more powerful cellular and humoral immune responses.Moreover,prophylactic vaccination by IMQ-MPLA-OVA-LPNPs effectively suppressed tumor growth and increased survival efficacy.Hence,the nanovaccines we fabricated can effectively co-deliver antigens and different TLR agonists and realize coordinated stimulation of DCs in a spatio-temporal manner for enhanced immune responses,which provides a promising strategy for cancer immunotherapy.
文献关键词:
作者姓名:
Nannan Wang;Yueyue Zuo;Shengjie Wu;Chenlu Huang;Linhua Zhang;Dunwan Zhu
作者机构:
Tianjin Key Laboratory of Biomedical Materials,Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy,Institute of Biomedical Engineering,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300192,China
引用格式:
[1]Nannan Wang;Yueyue Zuo;Shengjie Wu;Chenlu Huang;Linhua Zhang;Dunwan Zhu-.Spatio-temporal delivery of both intra-and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses)[J].药学学报(英文版),2022(12):4486-4500
A类:
nanovaccine,LPNPs,nanovac,nanovaccines
B类:
Spatio,delivery,both,intra,extracellular,toll,like,agonists,enhancing,specific,immune,responses,For,cancer,immunotherapy,triggering,receptors,TLRs,dendritic,cells,DCs,potentiate,Nevertheless,generate,robust,long,lived,well,designed,should,consider,different,locations,antigens,combinations,synergistically,optimal,antitumor,immunity,Here,fabricated,lipid,polymer,hybrid,nanoparticles,spatio,temporally,model,ovalbumin,OVA,surface,layer,TLR4,monophosphoryl,MPLA,within,TLR7,imiquimod,IMQ,core,activate,adaptive,exhibited,narrow,size,distribution,mean,diameter,zeta,potential,mV,showed,high,loading,around,encapsulation,efficiency,Our,data,revealed,that,great,biocompatibility,excellent,ability,internalization,thereby,promoting,maturation,cytokines,production,Compared,Free,promoted,uptake,lysosome,escape,depot,migration,secondary,lymphatic,organs,In,vivo,immunization,dual,induced,more,powerful,humoral,Moreover,prophylactic,vaccination,effectively,suppressed,growth,increased,survival,efficacy,Hence,realize,coordinated,stimulation,manner,enhanced,which,provides,promising,strategy
AB值:
0.501305
相似文献
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
Jingjing He;Xinxin Xiong;Han Yang;Dandan Li;Xuefei Liu;Shuo Li;Shuangye Liao;Siyu Chen;Xizhi Wen;Kuai Yu;Lingyi Fu;Xingjun Dong;Kaiyu Zhu;Xiaojun Xia;Tiebang Kang;Chaochao Bian;Xiang Li;Haiping Liu;Peirong Ding;Xiaoshi Zhang;Zhenjiang Liu;Wende Li;Zhixiang Zuo;Penghui Zhou-State Key Laboratory of Oncology in Southern China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou,China;Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,China;Guangdong Laboratory Animals Monitoring Institute,Guangdong Key Laboratory of Laboratory Animals,Guangzhou,China;Guangzhou Finelmmune Biotechnology Co.,LTD,Guangzhou,China
Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity
Ying Gao;Xueping Zheng;Boyang Chang;Yujie Lin;Xiaodan Huang;Wen Wang;Shirong Ding;Weixiang Zhan;Shang Wang;Beibei Xiao;Lanqing Huo;Youhui Yu;Yilin Chen;Run Gong;Yuanzhong Wu;Ruhua Zhang;Li Zhong;Xin Wang;Qiuyan Chen;Song GaoHu;Zhengfan Jiang;Denghui Wei;Tiebang Kang-Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou,Guangdong,China;Department of Interventional Radiology,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China;Department of Abdominal Oncology,The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University,Zhuhai,Guangdong,China;Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education,School of Life Sciences,Peking University,Beijing,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Pharmacological inhibition of MyD88 suppresses inflammation in tubular epithelial cells and prevents diabetic nephropathy in experimental mice
Qiu-yan Zhang;Su-jing Xu;Jian-chang Qian;Li-bin Yang;Peng-qin Chen;Yi Wang;Xiang Hu;Ya-li Zhang;Wu Luo;Guang Liang-Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Medical Research Center,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China;School and Hospital of Stomatology,Wenzhou Medical University,Wenzhou 325027,China;Department of Endocrinology,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou 325035,China;School of Pharmaceutical Sciences,Hangzhou Medical College,Hangzhou 311399,China;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325001,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。